{
  "id": "6020a7391cb411341a00007e",
  "type": "yesno",
  "question": "Is Benralizumab effective for Chronic Spontaneous Urticaria?",
  "ideal_answer": "Yes, the anti-IL-5 antibody benralizumab has been reported to reduce Chronic Spontaneous Urticaria symptoms.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30015639",
    "http://www.ncbi.nlm.nih.gov/pubmed/31446134",
    "http://www.ncbi.nlm.nih.gov/pubmed/32224275",
    "http://www.ncbi.nlm.nih.gov/pubmed/33685605"
  ],
  "snippets": [
    {
      "text": "Finally, treatments aimed at reducing eosinophil accumulation and activation, such as the anti-IL-5 antibodies mepolizumab, reslizumab, and benralizumab, have been reported to reduce CSU symptoms. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32224275",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The treatments that are under clinical trials for CSU are anti-IgE treatments such as ligelizumab, molecules targeting intracellular signaling pathways such as spleen tyrosine kinase inhibitors, surface inhibitory molecules such as siglec-8, anti-IL-1s such as canakinumab, Bruton kinase (BTK) inhibitors such as GDC-0853 and anti-IL-5s such as benralizumab and mepolizumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30015639",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "f-label use of dupilumab, reslizumab, mepolizumab, and benralizumab can be effective in CU. Ligel",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31446134",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Finally, treatments aimed at reducing eosinophil accumulation and activation, such as the anti-IL-5 antibodies mepolizumab, reslizumab, and benralizumab, have been reported to reduce CSU symptoms.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32224275",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ments aimed at reducing eosinophil accumulation and activation, such as the anti-IL-5 antibodies mepolizumab, reslizumab, and benralizumab, have been reported to reduce CSU symptoms. Clearly, a new pi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32224275",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ormation on the effects of the off-label use, in CSU, of biologics licensed for the treatment of other diseases, including dupilumab, benralizumab, mepolizumab, reslizumab, and secukinumab. Finally, we discuss",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33685605",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ", B cells, T cells and eosinophils. The treatments that are under clinical trials for CSU are anti-IgE treatments such as ligelizumab, molecules targeting intracellular signaling pathways such as spleen tyrosine kinase inhibitors, surface inhibitory molecules such as siglec-8, anti-IL-1s such as canakinumab, Bruton kinase (BTK) inhibitors such as GDC-0853 and anti-IL-5s such as benralizumab and mepolizumab.SUMMARY: The ongoing clinical trials on new targets of treatment hold new hopes not only for a better care of the disease but also a better understan",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30015639",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}